This month I expect CMS to finalize its proposed national coverage decision (NCD) [1] for lung cancer screening (LCS). This means that lung cancer will become a covered benefit in all insurance plans, and more of our patients will have access to this life saving innovation. Despite the overwhelming favorable results of the National Lung Screening Trial (NLST) [2] and the research from the International Early Lung Cancer Action Program [3], it was an uphill battle to convince payers and policymakers that lung screening should be a covered benefit. Beginning with testimony and comments for the US Preventative Services Task Force nearly 2 year ago, physician volunteers and ACR staff members worked tirelessly on behalf of radiologists and our patients to ensure LCS because a covered service. You can read more details about how the College influenced public policy for LCS in my column in the February ACR Bulletin [4]. The arduous process to make LCS for high-risk individuals a covered benefit demonstrates that focus on outcomes and cost-effectiveness will become the new paradigm in health care research. At issues more than “Can we do it safely and effectively?” but also “Should we do it, and is it cost effective for the population as a whole?” and the process of moving new innovations from research to practice to public policy is recognized in the ACR’s Strategic Plan [5] as a goal area. From the ability to coordinate multicenter trials to developing parameters for clinical practice, to leveraging its economics, political, and advocacy expertise, the College stands poised and ready to help its members move radiology’s next big innovation through the process.